CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later.
Adolescent
Adult
Aged
Case-Control Studies
Cyclin-Dependent Kinase Inhibitor p16
/ genetics
Female
Genetic Counseling
/ methods
Genetic Testing
/ methods
Heterozygote
Humans
Male
Melanins
/ metabolism
Middle Aged
Mutation
Pedigree
Prospective Studies
Radiation Exposure
/ statistics & numerical data
Sunburn
/ epidemiology
Sunlight
/ adverse effects
Young Adult
CDKN2A/p16
familial melanoma
genetic counseling and testing
sun protection
sunburns
Journal
Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
05
01
2019
accepted:
02
07
2019
pubmed:
3
8
2019
medline:
9
6
2020
entrez:
3
8
2019
Statut:
ppublish
Résumé
This study investigated whether genetic counseling and test reporting for the highly penetrant CDKN2A melanoma predisposition gene promoted decreases in sun exposure. A prospective, nonequivalent control group design compared unaffected participants (N = 128, M Both carriers and no-test control participants exhibited a decrease one year later in daily UVR dose (B = -0.52, -0.33, p < 0.01). Only carriers exhibited a significant decrease in skin pigmentation at the wrist one year later (B = -0.11, p < 0.001), and both carriers and no-test control participants reported fewer sunburns than noncarriers (p < 0.05). Facial pigmentation did not change for any group. Noncarriers did not change on any measure of UVR exposure. These findings support the clinical utility of disclosing CDKN2A test results and providing risk management education to high-risk individuals.
Identifiants
pubmed: 31371819
doi: 10.1038/s41436-019-0608-9
pii: S1098-3600(21)01103-5
pmc: PMC6946876
mid: NIHMS1539657
doi:
Substances chimiques
CDKN2A protein, human
0
Cyclin-Dependent Kinase Inhibitor p16
0
Melanins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
26-34Subventions
Organisme : NCRR NIH HHS
ID : UL1 RR025764
Pays : United States
Organisme : NCI NIH HHS
ID : N01PC35141
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA193193
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA158322
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000105
Pays : United States
Références
Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. Health Psychol. 2009;28:510–518.
doi: 10.1037/a0014778
Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA. 2008;299:1320–1334.
doi: 10.1001/jama.299.11.1320
Stoffel EM, Mercado RC, Kohlmann W, et al. Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. Am J Gastroenterol. 2010;105:1851.
doi: 10.1038/ajg.2010.120
Chai X, Friebel TM, Singer CF, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;148:397–406.
doi: 10.1007/s10549-014-3134-0
Schwartz MD, Isaacs C, Graves KD, et al. Long term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer. 2012;118:510–517.
doi: 10.1002/cncr.26294
Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97:1507–1515.
doi: 10.1093/jnci/dji312
Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894–903.
doi: 10.1093/jnci/94.12.894
Taber JM, Aspinwall LG, Kohlmann W, Dow R, Leachman SA. Parental preferences for CDKN2A/p16 testing of minors. Genet Med. 2010;12:823–838.
doi: 10.1097/GIM.0b013e3181f87278
Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol. 2003;15:157–161.
doi: 10.1097/00001622-200303000-00007
Gerstenblith MR, Goldstein AM, Tucker MA, Fraser MC. Genetic testing for melanoma predisposition: current challenges. Cancer Nurs. 2007;30:454–461.
doi: 10.1097/01.NCC.0000300165.98391.e7
Bergenmar M, Brandberg Y. Sunbathing and sun protection behaviors and attitudes of young Swedish adults with hereditary risk for malignant melanoma. Cancer Nurs. 2001;24:341–350.
doi: 10.1097/00002820-200110000-00002
Aspinwall LG, Leaf SL, Kohlmann W, Dola ER, Leachman SA. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol. 2009;60:745–757.
doi: 10.1016/j.jaad.2008.12.034
Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45–60.
doi: 10.1016/j.ejca.2004.10.016
Frieser MJ, Wilson S, Vrieze S. Behavioral impact of return of genetic test results for complex disease: systematic review and meta-analysis. Health Psychol. 2018;37:1134–1144.
doi: 10.1037/hea0000683
Hollands GJ, French DP, Griffin SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016;352:i1102.
doi: 10.1136/bmj.i1102
Glanz K, Volpicelli K, Kanetsky PA, et al. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev. 2013;22:607–614.
doi: 10.1158/1055-9965.EPI-12-1174
Aspinwall LG, Taber JM, Kohlmann W, Leaf SL, Leachman SA. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. Genet Med. 2014;16:846–853.
doi: 10.1038/gim.2014.37
Perna FM, Dwyer LA, Tesauro G, et al. Research on skin cancer-related behaviors and outcomes in the NIH grant portfolio, 2000-2014: Skin Cancer Intervention Across the Cancer Control Continuum (SCI-3C). JAMA Dermatol. 2017;153:398–405.
doi: 10.1001/jamadermatol.2016.6216
Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Genet Med. 2009;11:265–278.
doi: 10.1097/GIM.0b013e3181993175
Aspinwall LG, Stump TK, Taber JM, et al. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk. Transl Behav Med. 2018;8:29–43.
doi: 10.1093/tbm/ibx011
Taber JM, Aspinwall LG, Stump TK, Kohlmann W, Champine M, Leachman SA. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone. J Behav Med. 2015;38:740–753.
doi: 10.1007/s10865-015-9648-z
Eliason MJ, Larson AA, Florell SR, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol. 2006;126:660–666.
doi: 10.1038/sj.jid.5700094
Climate Prediction Center. Daily UV index, Salt Lake City, UT, 2011. 2012. http://www.cpc.ncep.noaa.gov/products/stratosphere/uv_index/gif_files/slc_11.png .
Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol. 1999;17:3245–3251.
doi: 10.1200/JCO.1999.17.10.3245
Kefford RF, Salmon J, Shaw HM, Donald JA, McCarthy WH. Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet. 1991;51:45–55.
doi: 10.1016/0165-4608(91)90007-H
Hansen CB, Wadge LM, Lowstuter K, Boucher K, Leachman SA. Clinical germline genetic testing for melanoma. Lancet Oncol. 2004;5:314–319.
doi: 10.1016/S1470-2045(04)01469-X
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.
doi: 10.1016/S0895-4356(00)00321-8
Allen M, McKenzie R. Enhanced UV exposure on a ski-field compared with exposures at sea level. Photochem Photobiol Sci. 2005;4:429–437.
doi: 10.1039/b418942f
Liley B, Liley J, Allen M, Robinson J, McKenzie R, Team U-VD. Personal exposures to UV radiation in New Zealand. Queensland, Australia: NIWA UV Workshop; 2010.
Gies P, Glanz K, O’Riordan D, Elliott T, Nehl E. Measured occupational solar UVR exposures of lifeguards in pool settings. Am J Ind Med. 2009;52:645–653.
doi: 10.1002/ajim.20722
Tuchin VV. Tissue optics: light scattering methods and instruments for medical diagnosis. Bellingham, WA: SPIE Press; 2007.
doi: 10.1117/3.684093
Glanz K, Yaroch AL, Dancel M, et al. Measures of sun exposure and sun protection practices for behavioral and epidemiologic research. Arch Dermatol. 2008;144:217–222.
doi: 10.1001/archdermatol.2007.46
Raudenbush SW, Bryk AS. Hierarchical linear models: applications and data analysis methods. Thousand Oaks, CA: Sage; 2002.
Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Psycho-Oncology. 2013;22:276–289.
pubmed: 23382133
Witte K. Putting the fear back into fear appeals—the extended parallel process model. Commun Monogr. 1992;59:329–349.
doi: 10.1080/03637759209376276
Cameron LD, Marteau TM, Brown PM, Klein WM, Sherman KA. Communication strategies for enhancing understanding of the behavioral implications of genetic and biomarker tests for disease risk: the role of coherence. J Behav Med. 2012;35:286–298.
doi: 10.1007/s10865-011-9361-5
Riley BD, Culver JO, Skrzynia C, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns. 2012;21:151–161.
doi: 10.1007/s10897-011-9462-x
Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17:70–87.
doi: 10.1038/gim.2014.147
Leachman SA, Carucci J, Kohlmann W. et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61:677.e1–e14.
doi: 10.1016/j.jaad.2009.03.016
Leachman SA, Lucero OM, Sampson JE, et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 2017;36:77–90.
doi: 10.1007/s10555-017-9661-5
Aspinwall LG, Taber JM, Kohlmann W, Leachman SA. Psychological aspects of hereditary cancer risk counseling and genetic testing. In: Carr BI, Steel J, (eds.) Psychological aspects of cancer. Boston, MA: Springer; 2013. p. 31–64.
Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C.et al. Effects of communicating DNA‐based disease risk estimates on risk‐reducing behaviours. Cochrane Database Syst Rev. 2010 Oct 6;10:CD007275.
Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet. 2009;18:R9–17.
doi: 10.1093/hmg/ddp003